Back to News
Market Impact: 0.18
N-Zyme Biomedical Program Receives US$2.76 Million NIH Award to Advance Fosamprenavir for PPI-Refractory GERD
Source: Business Wire
Healthcare & BiotechPrivate Markets & Venture
N-Zyme Biomedical received a US$2.76 million NIH award to advance fosamprenavir as a potential treatment for proton-pump-inhibitor-refractory gastroesophageal reflux disease (GERD). The non-dilutive funding supports further development of the program but is unlikely to have broad market impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.32
More News
- Heidi CEO on AI in Healthcare, $900M valuation
- Anthropic in talks to lease 1 gigawatt from Stream Data Centers- The Information
- Guggenheim Names Top Stock Pick in Biotech Sector
- Binance invests $100 million in one-time rival Circle and expands its USDC partnership
- May Mobility's SPAC Merger: Is This a Road to Nowhere for Investors?
- Snorkel AI triples valuation to $3.5B as demand for AI training data booms